Biomaxima (BMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomaxima (BMX) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł1.01 Million ≈ $278.79K USD) by net assets (zł46.81 Million ≈ $12.88 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BMX equity to assets ratio to measure how much of total assets are equity-financed.
Biomaxima - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Biomaxima's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BMX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Biomaxima Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomaxima ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Trainline Plc
LSE:TRN
|
0.441x |
|
Noble Helium Ltd
AU:NHE
|
-0.026x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
N/A |
|
Ostasiatiske Kompagni A/S
CO:OKEAC
|
0.526x |
|
Profithol S.A.
MC:SPH
|
-0.745x |
|
Commcenter S.A.
MC:CMM
|
0.286x |
Annual Cash Flow Conversion Efficiency for Biomaxima (2009–2024)
The table below shows the annual cash flow conversion efficiency of Biomaxima from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Biomaxima (BMX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł47.33 Million ≈ $13.02 Million |
zł-152.00K ≈ $-41.83K |
-0.003x | -109.48% |
| 2023-12-31 | zł46.97 Million ≈ $12.93 Million |
zł1.59 Million ≈ $438.14K |
0.034x | -95.20% |
| 2022-12-31 | zł52.46 Million ≈ $14.44 Million |
zł37.06 Million ≈ $10.20 Million |
0.707x | +15726.93% |
| 2021-12-31 | zł29.19 Million ≈ $8.03 Million |
zł-132.00K ≈ $-36.33K |
-0.005x | -102.95% |
| 2020-12-31 | zł25.94 Million ≈ $7.14 Million |
zł3.97 Million ≈ $1.09 Million |
0.153x | -48.86% |
| 2019-12-31 | zł16.46 Million ≈ $4.53 Million |
zł4.93 Million ≈ $1.36 Million |
0.299x | +137.97% |
| 2018-12-31 | zł16.85 Million ≈ $4.64 Million |
zł2.12 Million ≈ $583.53K |
0.126x | +18.86% |
| 2017-12-31 | zł17.37 Million ≈ $4.78 Million |
zł1.84 Million ≈ $506.23K |
0.106x | +23.83% |
| 2016-12-31 | zł16.83 Million ≈ $4.63 Million |
zł1.44 Million ≈ $396.07K |
0.085x | -41.53% |
| 2015-12-31 | zł15.64 Million ≈ $4.30 Million |
zł2.29 Million ≈ $629.38K |
0.146x | +277.64% |
| 2014-12-31 | zł14.49 Million ≈ $3.99 Million |
zł561.02K ≈ $154.40K |
0.039x | -55.45% |
| 2013-12-31 | zł14.37 Million ≈ $3.96 Million |
zł1.25 Million ≈ $343.86K |
0.087x | +118.87% |
| 2012-12-31 | zł12.84 Million ≈ $3.53 Million |
zł-5.91 Million ≈ $-1.63 Million |
-0.460x | -297.21% |
| 2011-12-31 | zł7.85 Million ≈ $2.16 Million |
zł1.83 Million ≈ $504.32K |
0.234x | +1427.93% |
| 2010-12-31 | zł6.73 Million ≈ $1.85 Million |
zł102.89K ≈ $28.32K |
0.015x | -88.33% |
| 2009-12-31 | zł3.20 Million ≈ $879.33K |
zł418.32K ≈ $115.13K |
0.131x | -- |
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more